Loading...
XASE
STXS
Market cap205mUSD
Jul 16, Last price  
2.39USD
1D
6.22%
1Q
29.19%
Jan 2017
267.75%
IPO
-68.13%
Name

Stereotaxis Inc

Chart & Performance

D1W1MN
P/E
P/S
7.64
EPS
Div Yield, %
Shrs. gr., 5y
6.20%
Rev. gr., 5y
-1.41%
Revenues
27m
+0.55%
15,026,39027,191,70639,298,80940,365,17351,149,55554,051,23741,987,43246,562,43438,031,08135,011,27637,674,52432,164,11631,144,10029,346,61728,902,55026,630,03535,020,86228,147,00026,771,00026,918,000
Net income
-25m
L+22.40%
-43,557,835-45,719,770-48,121,514-43,885,974-27,494,457-19,923,487-32,031,175-9,238,427-68,757,589-5,202,441-7,352,775-5,286,720-5,887,410116,756-4,232,973-6,452,892-8,437,150-19,151,000-20,713,000-25,353,000
CFO
-8m
L-7.02%
-40,986,183-38,982,881-35,713,494-28,654,503-22,308,663-18,909,745-31,569,278-12,117,658-6,331,644-9,092,143-2,528,501-6,562,754-4,674,567-2,546,582-4,616,680-3,511,772-2,945,911-8,415,000-9,139,000-8,497,000
Earnings
Aug 11, 2025

Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
IPO date
Aug 12, 2004
Employees
130
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
26,918
0.55%
26,771
-4.89%
28,147
-19.63%
Cost of revenue
51,657
48,610
46,923
Unusual Expense (Income)
NOPBT
(24,739)
(21,839)
(18,776)
NOPBT Margin
Operating Taxes
859
Tax Rate
NOPAT
(24,739)
(21,839)
(19,635)
Net income
(25,353)
22.40%
(20,713)
8.16%
(19,151)
126.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
297
81
220
BB yield
-0.15%
-0.06%
-0.14%
Debt
Debt current
570
856
373
Long-term debt
11,442
10,552
11,349
Deferred revenue
1,637
1,654
Other long-term liabilities
8,254
43
51
Net debt
(205)
(8,410)
(17,452)
Cash flow
Cash from operating activities
(8,497)
(9,139)
(8,415)
CAPEX
(34)
(366)
(2,378)
Cash from investing activities
74
19,765
(22,094)
Cash from financing activities
297
81
220
FCF
(25,068)
(20,978)
(20,856)
Balance
Cash
12,217
19,818
28,430
Long term investments
744
Excess cash
10,871
18,479
27,767
Stockholders' equity
(556,288)
(532,022)
(511,303)
Invested Capital
581,980
560,923
550,751
ROIC
ROCE
EV
Common stock shares outstanding
85,183
80,702
76,061
Price
2.28
30.29%
1.75
-15.46%
2.07
-66.61%
Market cap
194,218
37.52%
141,229
-10.30%
157,447
-66.39%
EV
199,365
138,396
145,584
EBITDA
(23,770)
(21,244)
(18,347)
EV/EBITDA
Interest
484
Interest/NOPBT